Cystic fibrosis therapy that improves cell function granted EU approval

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/krisanapong detraphiphat)
(Image: Getty/krisanapong detraphiphat)

Related tags: Cystic fibrosis, Fda, Eu, Ema, Cell membrane, Cell therapy, Cell therapy manufacturing

Vertex was granted marketing authorization for its cystic fibrosis therapy in a combination regimen, marking the company’s third treatment for the condition to reach the market.

The drug, Symkevi (tezacaftor/ivacaftor) was given marketing authorization by the European Commission (EC) as a therapy for cystic fibrosis (CF) patients with two copies of the F508del mutation, and a single copy of one of the 14 mutations that causes protein channel activity.

It becomes the first treatment available in the European Union (EU) for this specific condition; it also offers another treatment option for patients with two copies of the f508del mutation, the most common mutation in cystic fibrosis.

A Vertex spokesperson told us, “A mutation in the genes of a person with CF may result in proteins that don’t make it to the cell surface, where they are normally located, or in proteins at the cell surface that doesn’t open enough.”

The EC’s marketing authorization was based on results from two Phase III studies. The studies showed treatment with Symkevi provided benefits across different CF populations – statistically, significant improvements in lung function were also seen.

The treatment was approved by the U.S. Food and Drug Administration in February 2018 and by Health Canada in June 2018.

“While treatment is advancing rapidly, many people living with CF still do not have a therapy that targets the cause of their form of the disease,”​ explained the spokesperson.

With this authorization though, targeted treatment for CF is another step closer, she added.

Symkevi combines active agents tezacaftor with ivacaftor, also known by the brand name Kalydeco – when combined they help improve the performance of the CFTR channel in CF patients.

Tezacaftor helps the CFTR protein onto the cell surface and ivacaftor then helps the CFTR ion channel to remain open for longer periods. Together the active agents improve the balance of water and salts in affected organs.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...


Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers

Follow us


View more